论文部分内容阅读
目的探讨 PCNA、CD44v6在肝细胞癌(HCC)组织的表达及其临床病理意义。方法采用 PCNA、CD44v6单克隆抗体,对83例 HCC 标本进行免疫组化染色。结果 PCNA、CIN4v6在 HCC 的阳性率分别为87.95%和53.01%。PCNA 在 Edmondson Ⅰ、Ⅱ、Ⅲ、Ⅳ级的阳性率分别为42.86%、89.47%、92.86%、100%,有显著性差异(P<0.01)。CD44v6在转移组的高表达率为39.29%,明显高于无转移组(10.91%,P<0.01)。CIN4v6在包膜完整组和不完整组的阳性率分别为35.42%和77.14%,有显著性差异(P<0.01)。CD44v6阳性病人的生存期明显短于 CD44v6阴性病人(P<0.05)。PCNA 和 CD44v6在 HCC 的表达呈正相关。结论 PCNA、CD44v6有望成为预测HCC 发生、发展、转移、预后的生物学指标。
Objective To investigate the expression and clinicopathological significance of PCNA and CD44v6 in hepatocellular carcinoma (HCC) tissues. Methods Immunohistochemical staining of 83 specimens of HCC was performed using PCNA and CD44v6 monoclonal antibodies. Results The positive rates of PCNA and CIN4v6 in HCC were 87.95% and 53.01%, respectively. The positive rates of PCNA in Edmondson I, II, III, and IV were 42.86%, 89.47%, 92.86%, and 100%, respectively, with significant differences (P<0.01). The high expression rate of CD44v6 in metastasis group was 39.29%, which was significantly higher than that of non-metastasis group (10.91%, P<0.01). The positive rates of CIN4v6 in the intact and incomplete capsule groups were 35.42% and 77.14%, respectively, with significant differences (P<0.01). The survival of CD44v6-positive patients was significantly shorter than that of CD44v6-negative patients (P<0.05). There was a positive correlation between the expression of PCNA and CD44v6 in HCC. Conclusion PCNA and CD44v6 are expected to be biological indicators for the occurrence, development, metastasis and prognosis of HCC.